Prospective study of Prucalopride's Influence on Gastrointestinal Transit Times and Completeness of Examinations in Colon Capsule Endoscopy
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S461
DOI: 10.1055/s-0044-1783866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von A. Finta und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
This study aimed to investigate the impact of Prucalopride, a prokinetic medication, on gastrointestinal transit times in individuals undergoing colon capsule endoscopy.
Methods
Conducted from April 15 to November 1, 2023, the study included 100 participants who were stratified into two groups: Group A received Prucalopride after the capsule entered the small intestine, while Group B served as control without Prucalopride exposure. The study's primary objective was to identify the differences between the average gastrointestinal transit times of the two groups and assess the rate of incomplete examinations. Statistical analysis was performed using independent samples t-tests for transit times and a Chi-square test for incomplete exams.
Results
Group A, comprising 37 males and 13 females, showed an average age of 50 years and a BMI of 27.42. Group B, with 35 males and 15 females, had an average age of 44 years and a BMI of 24.67. The results of the comprehensive examination of Group A and Group B indicate that the average duration of stomach, small intestine and large intestine transit was 53 vs 58 (SD=35 vs 45), 83 vs 102 (SD=55 vs 68) and 189 vs 252 (SD=168 vs 269) mins, respectively, and the total examination time was 325 vs 410 (SD=163 vs 283) minutes. There was no significant difference between the two groups regarding stomach and large intestine transit time (p=0.4 and 0.13). However, the results indicate a statistically significant difference in small intestine and total examination transit time between the two groups (p=0.02 and 0.01). Group A had decrease in the mean number of incomplete cases in comparison to Group B (1 vs 6 instances, p=0.05). The group that received Prucalopride did not experience any notable adverse effects. Two cases of mild side effects, including nausea and vomiting were documented, and in one case, the use of NSAID was required to alleviate a headache.
Conclusions
In conclusion, Prucalopride administration during colon capsule endoscopy reduced the number of incomplete examinations significantly and influenced gastrointestinal transit times positively. This comprehensive analysis highlights Prucalopride's potential as a prudent therapeutic intervention to enhance diagnostic accuracy and improve patient outcomes during colon capsule examinations. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Finta, A., Szalai, M., Liebe, R., Madácsy, L., Lovasz, B., Barkai, L. J., & Tupcsia, F. (2024). Prospective study of Prucalopride's Influence on Gastrointestinal Transit Times and Completeness of Examinations in Colon Capsule Endoscopy. Endoscopy, 56(S 02 S 02), S461. https://doi.org/10.1055/s-0044-1783866
Vancouver
Finta A, Szalai M, Liebe R, Madácsy L, Lovasz B, Barkai LJ, et al. Prospective study of Prucalopride's Influence on Gastrointestinal Transit Times and Completeness of Examinations in Colon Capsule Endoscopy. Endoscopy. 2024;56(S 02 S 02):S461. doi:10.1055/s-0044-1783866
BibTeX
@article{Finta2024,
author = {Finta, A. and Szalai, M. and Liebe, R. and Madácsy, L. and Lovasz, B. and Barkai, L. J. and Tupcsia, F.},
title = {Prospective study of Prucalopride's Influence on Gastrointestinal Transit Times and Completeness of Examinations in Colon Capsule Endoscopy},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S461},
doi = {10.1055/s-0044-1783866}
}
EUVIMED